The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. PMID: 15228634, DOI: 10.1016/s1525-8610(04)70130-9.Peer-Reviewed Original ResearchConceptsAtypical antipsychoticsRate of extrapyramidal side effectsHigh-potency conventional antipsychoticsDays of risperidoneAtypical antipsychotic medicationsExtrapyramidal side effectsDay of olanzapineDouble-blind placebo-controlled trialConventional antipsychoticsNovel antipsychoticsAntipsychotic medicationTardive dyskinesiaTreating older patientsPsychopharmacological agentsAgitation symptomsNeurodegenerative disordersAntipsychoticsBehavioral agitationPlacebo-controlled trialOpen-label studyOlder patientsHigh-potencyAripiprazoleOlanzapineRisperidoneThe Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. DOI: 10.1097/01.jam.0000129822.54487.14.Peer-Reviewed Original ResearchLong-term care settingsOlder patientsAtypical antipsychoticsCare settingsNeurodegenerative disordersSide effectsDouble-blind placebo-controlled trialHigh-potency conventional antipsychoticsLong-term care patientsOpen-label studyPlacebo-controlled trialNewer atypical antipsychoticsOlder patient populationUse of quetiapineUse of risperidoneExtrapyramidal side effectsAtypical antipsychotic medicationsConventional antipsychoticsCare patientsTardive dyskinesiaNovel antipsychoticsAntipsychotic medicationPatient populationPsychopharmacologic agentsAgitation symptoms